Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021
Cash & Equivalents	0.44	0.07
Cash & Cash Equivalents	0.44	0.07
Cash Growth	498.63%	-
Total Current Assets	0.44	0.07
Goodwill and Intangibles	0.54	0.7
Other Long-Term Assets	0.06	0
Total Long-Term Assets	0.6	0.7
Total Assets	1.04	0.78
Current Debt	0	2.21
Other Current Liabilities	1.63	-0.26
Total Current Liabilities	1.63	1.94
Long-Term Debt	0.58	-
Total Long-Term Liabilities	0.58	0
Total Liabilities	2.22	1.94
Total Debt	0.59	2.21
Debt Growth	-73.42%	-
Retained Earnings	-4.4	-3.35
Shareholders' Equity	-1.18	-1.17
Net Cash / Debt	-0.15	-2.13
Working Capital	-1.2	-1.87

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).